Genome & Company (XKON:A314130) announced a private placement of 120,997 convertible preferred shares at a price of KRW 30,000 for gross proceeds of KRW 3,629,910,000 on April 16, 2020. The funding is being raised through third party allotment method. The preferred shares are convertible in to common shares during the period from April 25, 2020 to April 25, 2030. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 24, 2020.